Rock Hill

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• COPD5 trials
• Asthma4 trials
• Bronchiectasis1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Pulmonary arterial hypertension1 trial

Phase

• Phase 36 trials
• Phase 25 trials

Status

• Completed7 trials
• Recruiting4 trials
• Withdrawn1 trial

Lead sponsor

• AstraZeneca10 trials
• DalCor Pharmaceuticals1 trial
• Kinaset Therapeutics Inc1 trial

Running trials

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

  NCT07532265· Phase 2· Kinaset Therapeutics Inc· Source

  Contact: Kinaset investigative site

• Recruiting

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Recruiting

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· Phase 3· DalCor Pharmaceuticals· Source

  Contact: David Kallend, MBBS

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma2 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· Phase 2· AstraZeneca· Source

• Recruiting

  Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

  NCT06307665· Phase 3· AstraZeneca· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· AstraZeneca· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

  NCT05158387· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· AstraZeneca· Source

• Completed

  Tezepelumab COPD Exacerbation Study

  NCT04039113· Phase 2· AstraZeneca· Source

• Completed

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Source